BioImage to Use RNAx s RNAi-Knockdown Tool in Its Assay Technology

NEW YORK, Jan. 27 (GenomeWeb News) - RNAx yesterday said it will provide BioImage with its RNAi-knockdown technology.

The agreement will "complement" BioImage's Redistribution assay technology, and "vice versa."

"The goal of the agreement is to provide both RNAx's and BioImage's customers with both technologies from one source, the companies said in s statement.

Financial details of the agreement were not disclosed.

BioImage's Redistribution technology enables high-throughput, high-content screening on many targets of "current interest" in drug discovery, including a "range" of intracellular signaling molecules and cell-surface receptors, the companies said.

RNAx's technology, meantime, provides for automated validation of siRNAs and targets, including those for which BioImage has developed assays.